Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib

Sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Study ID
NCT06548867
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cabozantinib — DRUG
    Patients must have been treated with cabozantinib after one or more previous therapies for mRCC, as per clinical practise.

Study Details

CABOGEN is a Observational, retrospective, multicenter study that will enroll patients with metastatic clear cell renal carcinoma (mccRCC) treated with cabozantinib after one or more previous lines of treatment that included TKIs, immune checkpoint inhibitors or mTOR inhibitors.

Key Dates

Start date
May 28, 2024
Status verified
Aug 2024
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025

Study Design

Enrollment
80 participants (estimated)

Arms

  • Arm: Group A: long-lasting responders
    Patient long-lasting responders (PFS ≥9 months) to cabozantinib
  • Arm: Group B: primary refractories
    Patient progressed from the start to cabozantinib therapy within 3 months

Primary Outcome Measure

Genomic profiling [ Time Frame: 12 months ]

Central Contacts

Related Studies